c856ac956f
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2025-xx-pmc-glp1-psychiatric-disproportionality-faers-cvarod-daen.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
51 lines
4.3 KiB
Markdown
51 lines
4.3 KiB
Markdown
---
|
|
type: source
|
|
title: "Psychiatric Adverse Events Linked to GLP-1 Analogues: A Disproportionality Analysis in American, Canadian and Australian Adverse Event Databases"
|
|
author: "PMC (multiple authors)"
|
|
url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12630159/
|
|
date: 2025-01-01
|
|
domain: health
|
|
secondary_domains: []
|
|
format: paper
|
|
status: processed
|
|
processed_by: vida
|
|
processed_date: 2026-05-04
|
|
priority: medium
|
|
tags: [glp1, pharmacovigilance, eating-disorders, faers, disproportionality, psychiatric-adverse-events, cross-national]
|
|
intake_tier: research-task
|
|
extraction_model: "anthropic/claude-sonnet-4.5"
|
|
---
|
|
|
|
## Content
|
|
|
|
Cross-national pharmacovigilance disproportionality analysis using three national adverse event databases: FAERS (US), Canada Vigilance Adverse Reaction Online Database (CVAROD), and Database of Adverse Event Notifications (DAEN, Australia).
|
|
|
|
Key findings on eating disorders:
|
|
- Dulaglutide in FAERS: ROR = 1.47 (95%CI 1.26-1.71)
|
|
- Dulaglutide in DAEN (Australia): ROR = 17.66 (95%CI 2.45-127.37) — extremely elevated
|
|
- Tirzepatide in FAERS: ROR = 1.58 (95%CI 1.14-2.20)
|
|
- Note: Lower values than VigiBase study — reflects different database populations, denominator calculations, and the fact that this is US/CA/AU only vs. global VigiBase
|
|
|
|
Indication bias explicitly acknowledged: "The databases used in this study did not contain information on any pre-existing psychiatric conditions in patients reporting AEs" — researchers could not "distinguish between a medicine-induced reaction and an event related to a patient's ongoing health issues"
|
|
|
|
Causality conclusion: Researchers "cannot determine a causal relationship between medication use and AEs" — results should be "interpreted with caution and supplemented with clinical studies to confirm associations"
|
|
|
|
## Agent Notes
|
|
**Why this matters:** Confirms the eating disorder signal across US, Canadian, and Australian databases — the signal isn't US-specific or FAERS-specific. The Australian DAEN result (ROR 17.66 for dulaglutide) is particularly high, suggesting the signal may be even stronger in populations where dulaglutide has higher relative prescribing share. The cross-national consistency increases biological plausibility.
|
|
|
|
**What surprised me:** The ROR values here (1.47-1.58) are MUCH lower than the VigiBase aROR (4.17-6.80). This discrepancy is methodologically significant: VigiBase uses adjusted analysis (aROR controls for co-reported adverse events) while this study may not. The VigiBase analysis is the more reliable estimate — but the discrepancy between studies is itself a finding that an extractor should note.
|
|
|
|
**What I expected but didn't find:** CVAROD (Canadian) results for eating disorders — the paper either didn't find a significant signal there or the abstract/summary I accessed didn't report it.
|
|
|
|
**KB connections:**
|
|
- [[AI diagnostic triage achieves 97 percent sensitivity]] — parallel: pharmacovigilance databases have the same "signal vs. noise" sensitivity-specificity tradeoff
|
|
- [[healthcare AI regulation needs blank-sheet redesign]] — pharmacovigilance methodology also needs redesign for medication classes with behavioral effects
|
|
|
|
**Extraction hints:** Useful as CORROBORATING evidence for the VigiBase signal across additional databases. The Australian DAEN outlier (ROR 17.66) deserves specific mention — possible explanation is small denominator, different population, or higher awareness/reporting in Australia. NOT sufficient as a standalone source for the eating disorder claim — use alongside VigiBase as supporting evidence.
|
|
|
|
**Context:** This is a methodologically weaker study than the VigiBase analysis but provides geographic breadth. The indication bias limitation is shared by all pharmacovigilance databases.
|
|
|
|
## Curator Notes (structured handoff for extractor)
|
|
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
|
WHY ARCHIVED: Corroborating cross-national evidence for the eating disorder pharmacovigilance signal — extractor should use as secondary evidence, not primary
|
|
EXTRACTION HINT: Flag the discrepancy between this study's ROR (1.47-1.58) and VigiBase's aROR (4.17-6.80) in any claims that cite both — the methodological difference matters.
|